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The global obesity epidemic, dubbed “globesity” by the World Health Organisation, is a pressing public health issue. The aetiology
of obesity is multifactorial incorporating both genetic and environmental factors. Recently, epidemiological studies have observed
an association between microbes and obesity. Obesity-promoting microbiome and resultant gut barrier disintegration have been
implicated as key factors facilitating metabolic endotoxaemia.This is an influx of bacterial endotoxins into the systemic circulation,
believed to underpin obesity pathogenesis. Adipocyte dysfunction and subsequent adipokine secretion characterised by low grade
inflammation, were conventionally attributed to persistent hyperlipidaemia.Theywere thought of as pivotal in perpetuating obesity.
It is now debated whether infection and endotoxaemia are also implicated in initiating and perpetuating low grade inflammation.
The fact that obesity has a prevalence of over 600 million and serves as a risk factor for chronic diseases including cardiovascular
disease and type 2 diabetes mellitus is testament to the importance of exploring the role of microbes in obesity pathobiology. It is on
this basis that Massachusetts General Hospital is sponsoring the Faecal Microbiota Transplant for Obesity andMetabolism clinical
trial, to study the impact of microbiome composition on weight. The association of microbes with obesity, namely, adenovirus
infection and metabolic endotoxaemia, is reviewed.
1. Introduction
Obesity is a chronic multifactorial pathology driven by
the complex interaction between various factors. Extensive
research has implicated a number of genetic, epigenetic,
nutritional, and lifestyle factors. Furthermore, the composi-
tion of the gut microbiome has also been implicated in the
development of obesity. Irrespective of the specific causes
leading to obesity, it is a strong risk factor for the development
of cardiometabolic diseases, including insulin resistance, type
2 diabetes, and hypertension. The clinical consequences of
obesity extend further to include a spectrum of other diseases
such as malignancies, osteoarthritis, and obstructive sleep
apnoea [1, 2]. Moreover, obesity exerts a heavy toll in terms
of social and economic consequences [3, 4]. The rising
prevalence of both childhood and adult obesity is strongly
linked to caloric excess and the sedentary urban lifestyle
typical of “Westernised” countries [5]. There is, however,
growing evidence for a robust physiological process that
restricts the voluntary mechanisms to reduce body weight
by drastic changes in lifestyle. In this respect, obesity is
increasingly recognised as a disease rather than as a wilful
choice [6, 7].
Viral infection has been implicated as a contributing
factor in the aetiology of obesity in both animal and human
studies [8]. In addition, the gastrointestinal tract is home
to over 1014 bacteria that collectively form the intestinal
microbiome, with a joint genetic repertoire that is larger than
the human genome [9]. These symbiotic bacteria establish
and maintain the gut immune system and contribute to the
breakdown of complex nondigestible plant-derived polysac-
charides [10, 11]. Recent evidence links the gut microbiome
to the development of obesity andmetabolic disease [12].The
aim of this review is to present the epidemiological evidence
for the association betweenmicrobes and obesity, and discuss
the cellular and molecular mechanisms underpinning the
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inflammatory response that is central to adipocyte dysfunc-
tion in obesity pathobiology.
2. Conventional Perspective of Adipocyte
Dysfunction in Obesity Pathogenesis
2.1. Adipocyte Stress Response. Increased circulating levels
of triglycerides and glucose perturb metabolic homeostasis
and stimulate compensatory adipocyte hypertrophy and
hyperplasia [13]. Persistently elevated triglyceride and glu-
cose levels overwhelm the physiological response such that
decompensation (so-called adipocyte stress response) arises,
and thus adipocyte dysfunction ensues [14–16].
2.2. Chronic Low Grade Inflammation in Adipocyte Dysfunc-
tion. Adipocyte dysfunction is epitomised by a low grade
chronic inflammatory response, which is an integral feature
of obesity [20, 21]. It has been hypothesised that increased
caloric intake triggers inflammation leading to adipocyte dys-
function [16]. Adipose tissue is infiltrated with bonemarrow-
derived macrophages, and the density of these adipose tissue
macrophages (ATMs) is dependent on the degree of obesity.
The number of ATMs correlates with the degree of insulin
resistance [22]. Adipose tissue macrophages exhibit different
phenotypes depending on the degree of adiposity. ATMs
in lean nonobese individuals are anti-inflammatory (M2
macrophages) as opposed to ATMs in obese individuals that
express proinflammatory genes (M1 “classically-activated”
macrophages) [23].
In nonobese, insulin sensitive conditions, adipocytes
secrete factors that trigger alternative activation of macro-
phages. The obesity-induced changes in adipocyte gene ex-
pression trigger release of proinflammatory cytokines (TNF-
𝛼, MCP1) that lead to recruitment and activation of
macrophages. The activated M1 macrophages produce and
secrete other proinflammatory mediators, including IL-6,
TNF-𝛼, IL-1𝛽, and resistin. These mediators establish a pos-
itive feedback loop that further enhances insulin resistance
and inflammation [23]. Cytokines such as TNF𝛼, IL-6, and
IL-1𝛽 exert paracrine effects to activate inflammatory path-
ways.This leads to activation of JunN-terminal kinase (JNK),
inhibitor of 𝜅 B kinase 𝛽 (IKK), and other serine kinases,
which activate transcription factor targets (c-Fos/c-Jun) and
nuclear factor-kB (NF-kB) that stimulate transcription of
inflammatory pathway genes [24, 25].
IL-6 secreted by adipose tissuemacrophages is considered
a major inflammatory mediator. Primarily, IL-6 triggers
subclinical inflammation by instituting a vicious cycle that
includes the downregulation of lipoprotein transport to
peripheral tissues. This in turn increases plasma lipid levels
and promotes triglyceride release into the circulation. The
result is development of overt hypertriglyceridemia and
hyperlipidaemia, which serves to perpetuate the obesity
phenotype by presenting a constitutive signal for adipocyte
hypertrophy and hyperplasia. Adipocyte dysfunction thus
ensues. It has also been shown that IL-6 expression is
more pronounced in metabolically active visceral rather than
peripheral adipocytes [26].
2.3. Adipokine Secretion. Theadipocyte plays a key endocrine
role in the secretion of adipokines. This topic has been
extensively reviewed byOuchi et al. [27]. Adipokine secretion
is dysregulated in obesity with increased levels of obesity-
promoting adipokines. The expression of proinflammatory
proteins, particularly TNF-𝛼, may lead to a reduction in anti-
inflammatory adipokines, such as adiponectin which plays
a pivotal anti-inflammatory role [28]. Despite the extensive
research on adipose tissue inflammation, the direct causal
link between the events that trigger chronic inflammation
and the final metabolic outcome is still not clearly deter-
mined. This review will focus on presenting the evidence
linking microbes to adipose tissue dysfunction in the setting
of obesity.
3. Viral Infection and Obesity
3.1. Animal Viruses andObesity. Thefirst association between
viruses and obesity in animals was reported by Lyons
et al. Mice infected with canine distemper virus (CDV)
demonstrated adipocyte hypertrophy and hyperplasia in
the absence of CNS pathology [29]. CDV does not infect
humans but is antigenically related to the Paramyxoviridae
family that includes the measles virus. Subsequently other
investigators had demonstrated that the virus targets specific
hypothalamic regions and is associated with alteration of
various neuropeptide-signalling pathways, including leptin,
neuropeptide Y, and melanin-concentrating hormone [30–
33]. Rous-associated virus 7 (RAV-7) has also been associated
with a syndrome of obesity, stunted growth, hypercholes-
terolaemia, fatty liver, and thyroid dysfunction in chickens
[34]. Borna disease virus (BDV) has similarly been implicated
in rat obesity. This RNA virus causes a lymphomonocytic
inflammation of the hypothalamus, pancreatic islet cell
hyperplasia, and elevations of serum glucose and triglyceride
levels [35, 36]. BDV is neurotropic and has a wide range of
animal hosts. Seroepidemiological studies have implicated
BDV in neuropsychiatric diseases including schizophrenia
and depression in some populations, though the associations
have not been consistent [37–39].
Another animal model of virus-induced obesity impli-
cated the SMAM-1 avian adenovirus in chickens. SMAM-1
was shown to lead to increased adiposity independent of food
intake [40]. Subsequently, Dhurandhar et al. demonstrated
that body weight and BMI were higher in human subjects
positive for anti-SMAM-1 antibodies compared to those
negative for anti-SMAM-1 antibodies [41]. This was the first
reported association of viral infection with human obesity.
The transmissible spongiform encephalopathy scrapie that
infects cattle has also been linked to obesity. Kim et al. showed
that inoculation ofmice with theME7 strain of scrapie results
in obesity that is dependent on the hypothalamic-pituitary-
adrenal axis [42].
The few associations between viral infection and animal
obesity described above are clearly limited in translational
terms, yet are still crucial in demonstrating a strong associ-
ation between viral infection and obesity. Human adenovirus
36 (Ad-36) is a common human pathogen that has been
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linked to human obesity and adipocyte function through
different mechanisms and is discussed next.
3.2. Adenovirus 36 and Obesity—In Vivo Studies. The aden-
oviruses are an important group of widely prevalent human
pathogens that have been extensively studied. They are non-
enveloped icosahedral DNA viruses with a linear double
stranded genome that can infect a wide range of species
and tissues. Fifty-two human adenovirus serotypes have been
described. Their structural biology, genome, evolution, and
host cell immune response has been reviewed elsewhere [43–
45]. Clinically, they are responsible for a wide array of self-
limiting infections, primarily of the respiratory and gastroin-
testinal tracts. Furthermore, they are effective vectors for
gene-based immunotherapy and gene replacement strategies
[46]. Ad-36 has been associated with obesity in both animal
and human studies.
Ad-36 was first isolated from the faeces of a girl with
enteritis [47]. Genomic characterisation of the virus revealed
several unique features compared to other human aden-
oviruses that could possibly account for its unique tissue
tropism [48]. The first reported link between Ad-36 and
obesity was described in the year 2000 in animal models,
where chicken and mice inoculated with Ad-36 demon-
strated increased adipose tissue and decreased cholesterol
and triglyceride levels in the absence of CNS histopatho-
logical changes [49]. Ad-36 DNA was detected in adipose
tissue but not in skeletal muscle of the inoculated ani-
mals. Subsequently, other studies reproduced the adiposity-
promoting effects of Ad-36 in two non-human primate
models [50]. It was also shown that horizontal transmis-
sion of Ad-36 from infected to control animals produces
adiposity and is accompanied by a paradoxical reduction in
serum lipids [51]. Rats infected with Ad-36 demonstrate an
increase in weight and insulin sensitivity, visceral adipose
tissue expression of glycerol 3-phosphate dehydrogenase, and
peroxisome proliferator-activated receptor gamma (PPAR-
𝛾). CCAAT/enhancer-binding protein (C/EBP) alpha and
beta were greater in infected animals compared to controls
[52]. Kapila et al. reported that in a hamster model Ad-36
infection altered lipoprotein metabolism to produce a more
atherogenic profile, with diminished HDL-C and increased
LDL-C [53]. Viral DNA as a result of acute Ad-36 infection is
detected in multiple tissues early following inoculation [54].
3.3. Adenovirus and Adipocyte Biology. Vangipuram et
al. provided the first insight into the molecular mech-
anisms underpinning Ad-36-induced adipogenesis. The
authors demonstrated that viral infection in 3T3-L1 murine
preadipocytes induces differentiation and an increase in total
cell lipid content [55]. These features are not shared with
human adenovirus 2. Subsequently, Rathod et al. showed
that transient Ad-36 mRNA expression, but not viral DNA
replication, is required for preadipocyte differentiation [56].
The increased expression of PPAR-𝛾 and C/EBP reported
in animal studies is related to the proadipogenic effects
observed in vitro, as these genes are key transcription factors
that regulate adipocyte differentiation [52, 57]. A detailed
analysis of the cellular pathways involved in Ad-36-induced
adipogenesis showed that the viral E4 orf-1 gene stimulates
proadipogenic differentiation in both 3T3-L1 and human adi-
pose stem cells [58]. Furthermore, Ad-36 E4 orf-1 modulates
insulin sensitivity via activation of the phosphatidylinositol
3-kinase (PI3 K) pathway. This accounts for the observed
reduction in fasting insulin levels [52]. Studies also showed
that Ad-36 suppresses the expression of leptin mRNA and
improves glucose uptake in adipocytes [59].The role of Ad-36
in human adipose tissuewas further reinforced by studies that
demonstrated that the virus induces commitment, differenti-
ation, and lipid accumulation in human adipose-derived stem
cells [60]. Adipocyte differentiation and lipid accumulation
were observed in the absence of inducers of adipogenesis
and in osteogenic culture media. They were accompanied
by expression of the adipocyte-specific transcription factors
PPAR-𝛾 and C/EBP𝛽. Wang et al. also demonstrated that Ad-
36 significantly reduced fatty acid oxidation and increased
de novo lipogenesis in cultured human muscle cells [61].
Bouwman et al. further demonstrated in vitro that incubating
preadipocytes and adipocytes with adenovirus (subtypes 2
and 36), amongst other viruses, was responsible for increased
production of IL-6 which might contribute to chronic low
grade inflammation [62].
4. Adenovirus and Obesity—Epidemiological
Links
A number of investigators have studied the epidemiologic
association between Ad-36 infection and human obesity.
These investigations were carried out in different age groups
and population ethnicities and utilised various methodolo-
gies for viral detection. The salient findings of these human
seroepidemiologic studies have been recently described by
Ponterio andGnessi [63].Theunique genomic and proteomic
structure of Ad-36 limits antibody cross reactivity in serum
neutralization assays and further strengthens the reported
associations betweenAd-36 andhumanobesity.Themajority,
though not all studies, showed greater seropositivity for Ad-
36 in obesity, with extensive variation in seroprevalence
rates between countries. Three meta-analyses also showed
an association between Ad-36 infection and obesity in both
adults and children and are summarized in Table 1.
5. Gut Microbiome, Gut Barrier Integrity, and
Their Role in Obesity Pathogenesis
The role of bacteria and their associated products in the
pathogenesis of obesity has recently attracted considerable
interest. Moreover, it has been proposed that the composition
of the gut microbiome may contribute to obesity through
their effects on the gut barrier and beyond.
5.1. Gut Microbiome. The relatively recent technological
advances in genomics have revolutionized the study of the
intestinal microbiome. It is now possible to sequence mixed
microbial genetic material directly extracted from environ-
mental samples without prior laboratory culture of individual
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Table 1: Meta-analyses on the relationship between human adv-36 infection and obesity development in humans.
Study Number of cases Population size Study end points Major findings
Xu et al. [17]
(i) 9 cross-sectional
studies, 9 case-control
studies, and 6 cohort
studies
(i) 10191 study subjects
including adults and
children
(i) HAdV-36 infection rate
in obese and lean groups
(ii) BMI level and BMI
z-score in HAdV-36
positive and negative
groups
(i) HAdV-36 infection increased the
risk of obesity
(ii) HAdV-36
also increased the risk of weight gain
in adults, which was not observed in
children
Shang et al.
[18] (i) 11 case control studies
(i) 5739 study subjects
including adults and
children
(i) HAdV-36 infection and
obesity risk
(i) HAdV-36 infection is associated
with an increased risk of obesity
development
(ii) Risk is increased in children and
those with a BMI of ≥30 kg/cm2
Yamada et al.
[19]
(i) 10 cross-sectional
studies
(i) 2870 study subjects
including adults and
children
(i) Evaluating the
association between
HAdV-36 infection and
obesity/metabolic markers
(i) HAdV-36 infection is associated
with the risk of obesity and weight
gain, but not with abnormal metabolic
markers including waist circumference
species.This emerging field, known asmetagenomics, enables
a survey of the different microorganisms present in a specific
environment [64]. Several large-scale projects such as the
Human Microbiome Project have characterised microbial
genomes from hundreds of isolated human symbionts and
have shed light on the complex interplay between the human
host and itsmicrobial populace.The implications of composi-
tional changes in health and disease have also been elucidated
(http://hmpdacc.org/). Butyrate along with propionate and
acetate are short-chain fatty acids (SCFAs) derived from
the bacterial degradation of complex polysaccharides in the
gut [65]. They have important metabolic roles with butyrate
acting as a metabolic substrate for colonic epithelial cells.
The functions mediated by butyrate that are pertinent to the
pathogenesis of obesity include its role in the maintenance of
intestinal epithelial integrity, thereby preventing the translo-
cation of endotoxins produced by intestinal Gram-negative
bacteria across the gut barrier [66].
5.2.The Gut Barrier. Maintaining the integrity of the gut bar-
rier is critical in preventing contact between materials origi-
nating from the nonsterile external environment (gut lumen)
with the sterile systemic circulation [67]. Immunoprotection
is conferred by means of the gut-associated lymphoid tissue
(GALT) that is present on the mucosal surface and contains
antigen presenting cells capable of processing and presenting
exogenous antigens. The purpose of antigen presentation
is primarily to activate adaptive immunity [68]. The gut
barrier is composed primarily of enterocytes which adhere
to one another bymeans of tight junctions, desmosomes, and
adherens junctions [69]. This is important in order for dis-
criminative transport of material to occur effectively between
the gut lumen and the systemic circulation. Moreover, the
gut barrier’s role as a physical barrier to infection is key
in preventing dissemination of bacteria and their associated
products from the lumen into the systemic circulation [69].
The integral membrane proteins claudins and occludin, along
with cytoskeletal adaptor proteins ZO-1, ZO-2, and ZO-3,
have been demonstrated to facilitate paracellular transport
between enterocytes [70]. Disruption of the gut barrier at any
of these points results in indiscriminate dysregulated paracel-
lular transport [67, 71]. Furthermore, it has been suggested
that the integrity of the tight junction barrier is under strict
regulation of proinflammatory and anti-inflammatory sig-
nalling. Proinflammatory cytokines implicated in promoting
tight junction leakage include TNF-𝛼 and IFN-𝛾. Contrarily,
anti-inflammatory cytokines includingTGF-𝛽 and IL-10 have
been suggested to maintain the integrity of tight junctions by
downregulating proinflammatory signalling [72–76].
5.3. Dysbiosis. Failure to maintain a robust gut barrier,
termed gut barrier dysfunction,may lead to an alteredmicro-
biome composition, resulting inmicrobiome imbalance.This
is known as dysbiosis [67, 77]. The underlying causes of
dysbiosis are diverse, and a high fat diet poor in prebiotic-
containing nutrients has also been highlighted as a leading
cause [78]. A high fat diet has been shown to increase the ratio
of obesity-promoting bacteria in the microbiome [79].
In vivo studies have been conducted to demonstrate
the importance of gut microbiome composition. Widely
used models include the obesity mouse model ob/ob (leptin
deficient) and the db/db (leptin receptor mutant) mouse. In
a study conducted by Turnbaugh et al. it was shown that
transfecting sterile laboratory mice with microbiota from
ob/ob resulted in the expression of the obesity phenotype akin
to ob/obmice [80]. Moreover, sequencing studies performed
by Ley et al. compared themicrobiome of ob/obmice and lean
wild typemice.This revealed changes in two dominant bacte-
rial divisions: Bacteriodetes and Firmicutes. Firmicutes levels
were found to be increased in comparison to Bacteriodetes in
ob/obmice [81].
The situation is parallel in humans. Ley et al. extended
their study to human subjects who adopted either a low-
carbohydrate or a low-fat diet for weight control purposes,
during a one-year period. Follow-up during this period
demonstrated that a change in Bacteriodetes and Firmicutes
levels had occurred in study subjects compared to controls.
The change was such that from an initial elevated baseline
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Firmicutes : Bacteriodetes ratio, the ratio had normalised in
those subjects who lost weight and maintained a lean body
weight after a year, matching that of controls [82]. Further-
more, faecal microbiome studies in lean and obese monozy-
gotic and dizygotic twins established that the microbiome
is shared between relatives, though bacterial lineages were
individual-specific. A single dominant bacterial species was
not identified and it was concluded that the core microbiome
is shared in terms of genetic similarity rather than at a
dominant organismal level [83]. Certain studies in humans
have revealed beneficial commensal bacteria that strive to
maintain the integrity of enterocytes and thus the gut barrier.
These includeAkkermansiamuciniphila found in themucosal
mucus coating as well as Faecalibacterium prausnitzii [84, 85].
In dysbiosis such beneficial organisms are lost, and this is
coupled with endotoxin secretion by other harmful bacteria
that promote gut barrier breakdown, precipitating metabolic
endotoxaemia.
5.4. Metabolic Endotoxaemia. Central to the paradigm of
bacteria as contributors to the pathogenesis of obesity is
the concept of “metabolic endotoxaemia.” Put simply, this
is increased plasma bacterial lipopolysaccharide (LPS) levels
which are believed to originate from Gram-negative gut
microbiome that spill into the systemic circulation as a direct
result of gut barrier dysfunction [67, 77, 78]. A number
of systems have been implicated in mediating the “gut-to-
adipocyte axis” signalling, a term that we have coined to
describe the communication between the gut microbiome
and their associated endotoxins with adipocytes. Some sys-
tems have been proposed to function as gatekeepers and
others as mediators of toxin spillage in the setting of gut
barrier dysfunction.These systems include the endocannabi-
noid system, the apelinergic system, and the enteroendocrine
system [78, 86].
5.4.1. Endocannabinoid System. The endocannabinoid sys-
tem is a key mediator of molecular signalling between
LPS (chiefly originating from Gram-negative organisms)
and adipocytes [78, 87]. The two most studied bioac-
tive lipids are N-arachidonoylethanolamine (AEA) and 2-
arachidonoylglycerol (2-AG) which activate the G protein-
coupled receptors CB1 and CB2 [88]. Though the expression
of CB1 and CB2 was traditionally believed to be limited to
the central nervous system, recent evidence suggests that gas-
trointestinal expression also occurs [89]. In vivo and ex vivo
studies have implicated the CB1 receptor in gut-to-adipocyte
signalling.The exactmolecular signalling pathway thatmedi-
ates metabolic endotoxaemia has not yet been elucidated
[88, 90]. However, CB1 receptor activation has been shown
to modulate ion channels and activate different mitogen-
activated protein kinase (MAPK) pathways (p42/p44MAPK,
p38 MAPK, and c-Jun N-terminal kinase). It has also been
implicated in the inhibition of adenylyl cyclase in tissues and
cells.The aforementioned actions have been attributed toGi/o
proteins. In the case of MAPK pathways, aside from Gi/o
proteins, PI3 K also mediates CB1 receptor activation [91].
Furthermore, CB1 receptor stimulation results in activation
of inwardly rectifying K+ channels [92]. Similarly, L-type
voltage-gated calcium channel activity was also shown to be
targeted by CB1 receptor activation in cat cerebral arterial
muscle and neonatal rat nucleus tractus solitarius.The effects
here were primarily inhibitory [93, 94].
Among the wide array of physiological effects mediated
by the endocannabinoid system, the one most pertinent to
obesity is mainly increased energy intake and storage [95,
96]. Interestingly, the administration of the CB1 antagonist
SR141716 in humans is accompanied by decreased body
weight and anorexigenic effects [78]. Furthermore, to inves-
tigate the manner in which CB1 receptor agonist treatment
or LPS treatment gives rise to the metabolic features of diet-
induced obesity, mice were chronically treated with low-dose
LPS before and during a high fat challenge. The plasma LPS
levels were significantly increased (metabolic endotoxaemia)
as well as mRNA levels of the macrophage markers F4/80
and CD11c in adipose tissue. The increased macrophage
mRNAmarkers suggestedmacrophage infiltration in adipose
tissue [90]. This study clearly demonstrates a cause and
effect relationship between LPS inoculation and mediators of
inflammation.
It is therefore believed that one of the manners by which
endotoxaemia promotes obesity is through the upregulation
of the endocannabinoid system, thereby indirectly promoting
adipogenesis [97]. Endotoxaemia has also been implicated in
setting up chronic low grade inflammation in obesity, which
is in keeping with experimental evidence in animal models
[78].
5.4.2. Apelinergic System. Apelin is a peptide involved in the
regulation of the central nervous, gastrointestinal, cardiovas-
cular, and immune systems. It is also an adipokine secreted
by mature adipocytes in mice and humans and mediates its
effects via the APJ receptor [98]. It has been suggested as a
negative regulator of obesity, though its precise mechanisms
in this capacity are yet to be unravelled [87]. A myriad
of signalling cascades are triggered upon activation of APJ
receptor, the endpoint of which is the activation or repression
of a number of transcription factors. Coupling of the APJ
receptor to Gq/11 stimulates PLC-𝛽 signalling and subsequent
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to
IP3 and diacylglycerol (DAG). DAG activates PKC which
then activates the Ras protein. The Ras cascade can proceed
by activating either the MAPK or JNK pathways. An alter-
native signalling pathway also exists, where the APJ receptor
is coupled to Gi/o. This pathway activates the MAPK cascade
via PKC and it can also activate PI3K, which in turn activates
Akt and mammalian target of rapamycin (mTOR). mTOR
activates both p70S6K and endothelial nitric oxide synthase
(eNOS). In addition, adenylate cyclase is inhibited by Gi/o,
whereas Gs increases cyclic AMP synthesis from ATP and
activates the PKA pathway [99].
A hyperactive endocannabinoid system in the pathogenic
setting of obesity, alongwith low grade chronic inflammation,
has been suggested as the culprits for the augmentation
in apelin levels observed in obese animal models and
humans [87]. The mechanisms of communication between
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the endocannabinoid and apelinergic systems are poorly
understood. It has been previously shown that inflamma-
tion regulates both apelin and APJ mRNA expression [87].
Intraperitoneal administration of apelin in obese and normal
mice over a 14-day period induced weight loss independent
of food intake [100]. In addition, it was demonstrated in
db/dbmice that apelin and APJmRNA levels showed twofold
and threefold respective increase [87]. Possibly, a hyperactive
endocannabinoid system and low grade inflammation may
directly or indirectly trigger activation of the apelinergic
system as a homeostatic mechanism to counteract obesity.
5.4.3. Enteroendocrine System. The L-cells of the enteroen-
docrine system are neuroendocrine cells expressed from the
duodenum to the rectum and produce glucagon-like peptides
1 and 2 (GLP-1 and GLP-2) [101, 102]. GLP-1 is an incretin
hormone known for its role in glucose homeostasis and
energy balance. It also inhibits glucagon secretion, reduces
food intake, and delays gastric emptying. Its role extends
beyond glucose homeostasis [102]. GLP-1 may be implicated
in antagonising the effects of metabolic endotoxaemia by
regulating epithelial cell proliferation, thus sustaining the
gut barrier [103]. In order to determine the mechanisms
through which intestinal proliferation is promoted by GLP-
1, C57BL/6 WT mice were treated with the GLP-1 receptor
agonist exenatide (EX-4: exendin-4) for a period of one week.
Increased weight, length, and weight per unit length of small
bowel and large were noted. These effects were also observed
with chronic (1 month) treatment of C57BL/6 WT mice.
However, this effect was not evident in 𝐺𝑙𝑝1r−/− mice who
were subjected to the same treatment over the same period
of time. Upregulated gene expression profiles included IGF1,
IGF1R, and areg. A conditional deletion of the IGF1R gene
from intestinal epithelial cells and subsequent Liraglutide
and Exenatide administration increased both small bowel
and colon weight and length. Activation of GLP-1 receptor
signalling in Fgf7−/− mice failed to increase small bowel and
colon mass in the absence of Fgf7. It was therefore deduced
that GLP-1 receptor agonists activate components of IGF-
1 and ErbB signalling pathways and that the proliferative
actions of GLP-1 receptor agonists are selectively mediated
through mechanisms requiring Fgf7 [102].
Similarly, GLP-2 has been shown to induce proliferation
in vitro in Caco-2 cells. The cells were subcultured in the
presence or absence of GLP-2 as well as different kinase
antagonist concentrations. These included Genistein (global
tyrosine kinase inhibitor), LY294002 (PI3K) inhibitor, and
PD 098059 (mitogen-activated/extracellular signal-regulated
kinase (MEK) inhibitor). Cells which were administered
GLP-2 exhibited more than 10-fold increase in proliferation,
a response which was blunted by Genistein, LY294002, and
PD 098059 in a dose-dependent fashion. Such a response was
attributed at least in part to both the PI 3-kinase and the
MAPK pathways [104].
Further studies in humans are warranted in order to
elucidate the underlying mechanisms pertinent in gut pro-
liferation mediated by both GLP-1 and GLP-2. However,
the experimental models provide clear evidence of the
involvement of the enteroendocrine system in intestinal
proliferation.
6. The (Microbial Hypothesis) in
Inflammation of Adipocyte Dysfunction
6.1. Limitations of the Classical Hypothesis of Adipocyte Dys-
function. In light of the previously discussed viral infection
and bacterial endotoxaemia, the conventional perspective of
adipocyte dysfunction in the pathogenesis of obesity clearly
exhibits a number of limitations in substantially explaining
adipocyte inflammation as a feature of obesity pathogenesis.
Firstly, the trigger for inflammatory cell recruitment and
secretion of inflammatory cytokines in adipose tissue is
poorly accounted for, with no experimental evidence in
existence to the best of our knowledge [105–107]. Secondly,
inflammation in obesity is described as being “sterile” in
nature [105]. No consideration has therefore been given to the
contributory role ofmicrobes ormicrobial endotoxins such as
bacterial LPS in initiating and perpetuating chronic low grade
inflammation.
6.2. Postulated Inflammatory Triggers of Adipocyte Dysfunc-
tion. The physiological goal of inflammation is primarily to
eliminate an insult which the body deems alien and noxious.
This is often employed via the innate and subsequently
the adaptive immune responses should the insult persist.
The acute inflammatory response is therefore converted to
chronic inflammation in the setting of a persistent insult
[107]. It is therefore not unreasonable to propose that viral
infection and metabolic endotoxaemia may serve as trig-
gers of inflammation that underpin adipocyte dysfunction.
Mechanistically, we have subdivided possible triggers of
inflammation into “transient” and “persistent” factors on the
basis of chronicity.
6.2.1. Transient Inflammatory Triggers. In the case of viral
infection, it is plausible to suggest that acute repetitive
infections may serve as a transient factor that regularly
initiates acute inflammation.This is later converted to chronic
inflammation by background persistent factors.The infective
situation may be described as a repetitive acute-on-chronic
scenario. Repetitive infections may be explained by the fact
that obesity is associated with an increased susceptibility to
infection due to impaired systemic immune function [108].
6.2.2. Persistent Inflammatory Triggers. The chronic nature
of dysbiosis and subsequent metabolic endotoxaemia is in
keeping with the chronicity of inflammation observed in
obesity and may qualify as persistent factors. This may
therefore suggest a critical role for dysbiosis and endotox-
aemia in initiating and perpetuating chronic inflammation
via the persistent presence of bacterial LPS in the systemic
circulation. The repetitive acute-on-chronic viral infections
along with chronic dysbiosis and metabolic endotoxaemia
may therefore possibly act in a concerted manner to promote
chronic inflammation.
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6.3. Determinants of Low Grade Inflammatory Tone. The
characteristically low grade “subclinical” tone of inflam-
mation in obesity can also be accounted for. The resident
gut microflora is an essential component of gastrointestinal
physiology and its myriad role is beyond the scope of this
review. A degree of immunological tolerance is exerted so
as not to instigate an immune response against them, in
order to preserve their critical function [109, 110]. It has
been suggested that the gut microbiome regulates not only
local intestinal immunity but also systemic immunity [111].
It is therefore logical to suggest that the impaired systemic
immune function that occurs in obesity may at least in
part be attributed to dysbiosis and metabolic endotoxaemia,
therefore resulting in subclinical inflammation.
6.4. The Adipocyte as an Immune Cell. It has been demon-
strated that immature haematopoietic stem cells are present
in adipocytes, and mature adipocytes express membrane-
bound NADPH oxidase similar to that of phagocytic neu-
trophils [112]. It has also been suggested that the fact that
adipocytes and their progenitors share a common embryonic
origin with cells of the immune system rationalises the adi-
pogenic response to endotoxaemia (i.e., adipocyte expansion)
[108]. It is therefore plausible to propose that adipocyte
hypertrophy and hyperplasia (i.e., the obesity response) are
akin to an immune response mounted against an exogenous
antigen, in terms of immune cell replication and phagocyto-
sis. Therefore, perhaps the effects of the often recommended
healthy diet and exercise extend far beyond lipolysis and
weight loss. The beneficial effects of such measures may in
addition restore a healthy microbiome and thus eliminate
dysbiosis and endotoxaemia as triggers of obesity. Exercise-
induced hyperaemia and angiogenesis may serve to increase
circulatory transport of repair factors to regions of gut barrier
damage, promoting repair and resolution.
The “microbial hypothesis” attempts to address the lim-
itations of the classical hypothesis in explaining the trigger
of inflammation in adipocyte dysfunction, and the possible
role that microbes and microbial endotoxins may play in the
process. Rather than refute the classical hypothesis altogether,
this hypothesis acts to supplement the classical hypothesis.
It does so in terms of filling in the missing link in the
chain of events, taking into account the aforementioned
recent experimental data that have undoubtedly suggested a
critical role for microbes and microbial products in obesity
pathobiology.
7. Conclusion
Taken together, there is undoubtedly an association between
viral infection and metabolic endotoxaemia in the pathogen-
esis of obesity. However, proof of association, no matter how
appealing or robust, does not necessarily imply causation.
Since the obesity epidemic is recognised as being multifac-
torial in origin, a multifaceted approach to management is
therefore warranted. Infection treatment and prevention do
not formally feature in clinical practice guidelines given the
fact that basic science research in “infectobesity” is still at its
infancy, yet very promising. However, one should make no
mistake to undermine the overwhelming evidence in both
animalmodels and humans that suggest an important role for
infection and endotoxaemia in the development of obesity.
In fact, this is gaining prominence so much so that Mas-
sachusetts General Hospital is sponsoring the Faecal Micro-
biota Transplant forObesity andMetabolism clinical trial, the
first clinical trial to study the impact of gut bacteria on weight
(https://clinicaltrials.gov/ct2/show/NCT02530385). The trial
is currently at recruitment stage and due to commence soon.
The results of this trial are awaited anxiously by the scientific
community, as it could possibly cause a paradigm shift in our
understanding of obesity and alter themanagement course of
this epidemic.
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